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High levels of human immunodeficiency virus type 1 (HIV-1) replication, as reflected in HIV-1
RNA concentrations in blood and semen, probably contribute to both rapid disease progression and
enhanced sexual transmission. Semen and blood were collected from 49 Malawian and 61 US and
Swiss (US/Swiss) HIV-1–seropositive men with similar CD4 cell counts and no urethritis or exposure
to antiretroviral drugs. Median seminal plasma and blood plasma HIV-1 RNA concentrations were
3-fold (P  .034) and 5-fold (P  .0003) higher, respectively, in the Malawian men. Similar
differences were observed in subsets of the Malawian and US/Swiss study groups matched individu-
ally for CD4 cell count (P  .035 and P  .002, respectively). These observations may help explain
the high rates of HIV-1 sexual transmission and accelerated HIV-1 disease progression in sub-
Saharan Africa.
Most human immunode®ciency virus type 1 (HIV-1)±in- HIV-1 RNA measures independently predict prognosis in
North American and European populations [7], but HIV-1 RNAfected people live in regions of Africa and Asia, where hetero-
sexual transmission predominates [1]. The continued rapid concentrations in sub-Saharan Africans have not previously
been reported. In this study, we examined the hypothesis thatexpansion of this heterosexual epidemic likely re¯ects interac-
tions among many behavioral and biologic factors. Analogous levels of HIV-1 in blood and semen in a Malawian population
sampled in a cross-sectional fashion would exceed those into other sexually transmitted diseases (STDs), the HIV-1 inocu-
lum in semen is probably a major determinant of transmission a comparable group of North American and European men,
providing a biologic basis for the observed heterogeneity infrom men. In support of this hypothesis, plasma HIV-1 RNA
concentrations, which often predict semen levels [2, 3], corre- rates of HIV-1 transmission and progression.
late with transmission between stable partners [4]. Mucosal
STDs signi®cantly increase seminal plasma viral RNA [5],
Materials and Methodshelping to explain their association with HIV transmission.
HIV-1 disease may progress faster in sub-Saharan Africa
Study population. Forty-nine consecutive HIV-1±seropositivethan in North America and western Europe [6]. Single plasma
men attending dermatology clinics at Lilongwe Central Hospital
(Malawian subjects) who served as a control group for a previously
reported study [5] and 61 HIV-1±seropositive male volunteers
Received 4 August 1997; revised 6 January 1998. from infectious diseases clinics at the University of North Carolina
Presented in part: 4th Conference on Retroviruses and Opportunistic Infec- and the Kantonsspital, St. Gallen (US/Swiss subjects), were stud-
tions, Washington DC, 22±26 January 1997 (abstract 26). ied. The 61 US/Swiss men were an antiretroviral naive subset of
Informed consent was obtained from all patients participating in this study.
a larger cohort of men studied [3]. Clinic evidence of mucosal orThis research was conducted according to the human experimentation guide-
ulcerative STDs led to exclusion from the study. In Malawianlines of the US Department of Health and Human Services. The protocol was
approved by the University of North Carolina Committee on the Protection of men, urethral infection with Neisseria gonorrhoeae, Trichomonas
Human Rights and The Malawi Health Sciences Research Committee. vaginalis, or Chlamydia trachomatis was excluded by Gram's
Information contained herein does not necessarily re¯ect the views or poli-
stain, culture, and C. trachomatis ligase chain reaction (Uriprobecies of the US Agency for International Development.
LCR; Abbott Diagnostics, Abbott Park, IL) of urethral swabs.Financial support: US Agency for International Development (USAID) as
part of Family Health International's AIDS Control and Prevention (AIDS- Malawian men were con®rmed as HIV-1±seropositive by two
CAP) Project (623-02380A-00-4031-00); World Health Organization (award EIAs (HIV-1/HIV-2 EIA; Genetic Systems, Seattle; Murex HIV-
SD1/94/009); NIH (UO-31496 and DK-49381), NIH Of®ce of AIDS Research; 1 / 2, Murex Diagnostics, Dartford, UK), followed by Western
P®zer; Swiss National Science Foundation (32-38818.93).
blot (Organon Teknika, Durham, NC) for results that were equivo-Reprints or correspondence: Dr. Joseph J. Eron, Jr., Dept. of Medicine, CB#
cal. HIV-1 seropositivity was con®rmed in all US/Swiss men by7030, 547 Burnett-Womack Bldg., University of North Carolina, Chapel Hill,
NC 27599-7030 (jeron@med.unc.edu). Western blot.
* Present af®liations: Infectious Diseases Unit, Townsville General Hospital, Specimen collection and laboratory procedures. Semen was
Queensland, Australia (J.R.D.); The Henry M. Jackson Foundation, Rockville,
processed as previously described [2]. US/Swiss samples wereMaryland (B.L.G.).
diluted in 2.5 mL of transport medium before processing. Blood
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plasma (BP) was separated and frozen at 0707C within 1 day ofq 1998 by The University of Chicago. All rights reserved.
0022±1899/98/7706±0045$02.00 semen collection. HIV-1 RNA concentrations in BP and cell free
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seminal plasma (SP) were quanti®ed using nucleic acid sequence± US/Swiss men and BP from 42 and 49 men, respectively.
based ampli®cation assay (NASBA; Organon Teknika, Boxtel, Signi®cantly higher levels of HIV-1 RNA were observed in
The Netherlands) [2], with a sensitivity of 1000 RNA copies/mL. Malawian than in US/Swiss BP and SP (median, 15.5 1 104
T cell subsets were measured in blood collected from Malawian copies/mL vs. 2.88 1 104 copies/mL, P  .0003; and 1.51 1
men at the same time as BP for HIV-1 RNA quanti®cation. In the 104 copies/mL vs. 0.46 1 104 copies/mL, P  .034, respec-
US/Swiss men, the CD4 cell count closest to the time of semen
tively, ®gure 1A).
collection, within 1 month in each case, was used. HIV-1 subtype
Paired analysis compared SP RNA concentrations in 33 pairsin Malawian men was determined by envelope V3 peptide immu-
of Malawian and US/Swiss subjects individually matched fornoassay using antigens speci®c for clades A through F [8].
CD4 cell count (median CD4 cell counts, 299 cells/mL andStatistics. Samples containing undetectable HIV-1 RNA were
300/mL, respectively). BP HIV-1 RNA levels were availableassigned a value half the assay detection limit (500 copies/mL).
Arithmetic correction for dilution was made, except for undetect- for 22 of these pairs. As shown in ®gure 1B, median Malawian
able RNA levels. The Mann-Whitney U test was used for compari- SP HIV-1 RNA concentration was 1.70 1 104 copies/mL com-
sons between groups and Wilcoxon rank sum test for paired com- pared with 500 copies/mL (below detectable) in US/Swiss men
parisons. For paired analysis, individual Malawian and US/Swiss (P  .035), with a median BP RNA of 15.5 1 104 copies/mL
subjects were matched for CD4 cell counts within 10 cells/mL versus 2.34 1 104 copies/mL (P  .003).
of one another without knowledge of BP and SP HIV-1 RNA Distributions of SP and BP HIV-1 RNA concentrations in
concentrations. Linear regression was used to identify independent
the two study populations are illustrated in ®gures 1C and D.
predictors of BP and SP HIV-1 RNA.
Fifty-seven percent (24/42) of Malawian men had blood HIV-
1 RNA levels 125,000 copies/mL compared with only 20%
Results (10/49) of US/Swiss men (P  .0005, ®gure 1D). The BP RNA
level was below the assay detection limit of 1000 copies/mLCharacteristics of patient populations. Table 1 shows clinical
in 12% of US/Swiss compared with 10% of Malawian men;and demographic characteristics of the subjects. In all but 5 cases,
SP RNA was undetectable in 42% and 22%, respectively. Thedermatologic disorders in Malawian men were minor, including
differences between BP and SP log HIV-1 RNA values (equiva-super®cial mycosis, seborrheic dermatitis, super®cial bacterial in-
lent to ratios between absolute BP and SP RNA levels) offection, urticaria, pityriasis rosea, warts, molluscum contagiosum,
individual subjects were similar in Malawian and US/Swisseczema, psoriasis, and drug eruption. Five men had herpes zoster
groups (data not shown).or primary varicella infection. No US/Swiss man described sig-
Malawian origin and CD4 cell count correlated signi®cantlyni®cant symptoms at the time of sample collection.
with the BP HIV-1 RNA concentration and independently pre-Comparisons of HIV-1 RNA concentrations in blood and
dicted BP RNA level in multiple regression analysis (adjustedsemen. SP samples were collected from 49 Malawian and 61
total R2  .35, P  .0001 for absolute CD4 cell count, P 
.004 for country of origin). Although Malawian origin, CD4
cell count, BP RNA, and HIV-1 disease stage all individuallyTable 1. Clinical and demographic characteristics of 49 Malawian
and 61 US and Swiss (US/Swiss) HIV-1±seropositive men. correlated with SP HIV-1 RNA, the sole independent predictor
following multiple linear regression analysis was BP RNA
US/Swiss concentration (adjusted total R2  .24, P  .0012).
Malawian treatment-naive P*
Eight Malawian men had evidence of active systemic infec-
tions at the time of sampling (see table 1 footnote), while allMean age (years) { SD 32 { 7.5 35 { 8.0 .017
Median CD4 cell count US/Swiss subjects were clinically well. The actively infected
(cells/mL), interquartile range 305 (190±479) 339 (160±500) .73 men had marginally higher BP HIV-1 RNA levels than the
Asymptomatic (CDC stage A) 36 (73%) 52 (85%) .15 remainder of the Malawian group (median, 3.24 1 105 copies/
Symptomatic
mL [n  7] compared with 1.41 1 105 copies/mL, P  .39)(CDC stage B or C) 13 (27%) 9 (15%)
and similar SP RNA concentrations (median, 1.35 1 104 vs.Active systemic infection 8 (16%)² 0
Mode of HIV-1 acquisition ND 1.51 1 104 copies/mL, P  .98). When these 8 men were
Heterosexual 14 (23%) excluded from analysis, both BP and SP HIV-1 RNA concen-
Homosexual 37 (61%) trations remained signi®cantly higher in Malawian than US/
Intravenous drug users 10 (16%)
Swiss men (P  .002 and P  .04, respectively). The same
NOTE. In the Malawian group, 41 subjects had absolute CD4 cell counts observation held for paired analysis with matching for CD4
available, and 42 had CD4 percentages available. In the US/Swiss group, all cell count, when the ®ve pairs including an actively infected
had CD4 cell counts done. ND, not determined.
Malawian patient were excluded (P  .008 for comparison of* Continuous data were compared by Mann-Whitney U test, and dichoto-
mous variables were compared by Fisher's exact test. BP HIV-1 RNA concentrations and P  .006 for SP RNA).
² Includes 4 subjects with dermatomal herpes zoster, 1 with disseminated Of 42 Malawian men whose samples were submitted for
varicella-zoster infection, 1 with secondary syphilis, 1 with active tuberculosis
subtype analysis, 40 had typeable virus. Thirty-seven had anti-and possible drug-induced lupus, and 1 with possible tuberculosis (chronic
cough, fever, night sweats, and weight loss.) body directed only to peptide antigen speci®c for clade C, 1 had
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Figure 1. Comparison of blood (BP) and seminal plasma (SP)
HIV-1 RNA concentrations (expressed as log10 values) in antiretrovi-
ral-naive Malawian and US/Swiss groups. Distribution of values is
depicted in boxplots for subgroups matched individually for absolute
CD4 cell count (A) and by histograms of log10 SP (C) and BP (D)
HIV-1 RNA concentrations in US/Swiss (speckled bars) and Mala-
wian (®lled bars) subjects, plotted in multiples of 5 above detection
limit of 1000 copies/mL. In boxplots, horizontal lines represent me-
dian (25th and 75th percentiles), vertical lines extend to 10th and
90th percentiles, and small ®lled box is mean (calculated using 500
RNA copies/mL for values below assay detection limit).
antibodies cross-reactive to clades A and C, 1 had antibodies to late with improved prognosis [7]. We found Malawian origin
and residence to be a highly signi®cant predictor of the BPclades A, C, and F, and 1 had antibody to clade A only. All
US/Swiss men had acquired HIV-1 infection in the United HIV-1 RNA concentration, independent of CD4 cell count.
High levels of HIV-1 replication could account for more rapidStates or Switzerland and were considered likely to harbor
clade B virus [1]. disease progression in sub-Saharan Africa than in the United
States and Europe.
High levels of viral shedding in semen may partly explain the
Discussion
continuing rapid heterosexual spread of HIV-1 in sub-Saharan
Africa [1]. We found 3- to 4-fold higher concentrations of SPWe observed a 5- to 7-fold higher median BP viral RNA
concentration in HIV-1±infected Malawian men than in a HIV-1 RNA in Malawian men than in CD4 cell level±matched
US/Swiss subjects receiving no antiretroviral therapy. In bothgroup of untreated US and Swiss men with similar CD4 cell
counts. Recent studies indicate that blood levels of viral RNA groups, HIV-1 RNA levels in blood correlated with those in
SP, the BP concentration being the only independent predictorare powerful predictors of progression to AIDS and death inde-
pendent of CD4 cell count and other markers and that reduc- of seminal HIV-1 shedding. Blood-to-semen HIV-1 RNA ratios
did not differ between the 2 groups, suggesting that similartions in plasma HIV-1 RNA after antiviral drug therapy corre-
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factors were responsible for increased levels of virus in both The causes of the expanding heterosexual HIV-1 epidemics
in sub-Saharan Africa and southern Asia are not clear. Behav-body ¯uids in the Malawian men. Whether production of geni-
tal tract HIV-1 occurs in a separate biologic compartment, as ioral factors may provide a partial explanation. However, dis-
tinct biologic aspects of the virus, the host, and the environmentsuggested by previous studies [9], cannot be determined by the
data presented here. may be important determinants of regional patterns of HIV-1
spread and disease progression. The high HIV-1 RNA concen-A number of host- or virus-related factors could explain the
differences observed between BP and SP HIV-1 RNA levels trations in blood and semen in this African population probably
re¯ect interactions among genetic, immunologic, environmen-of the 2 groups. Immune activation by infection or vaccination
can reversibly elevate BP viral RNA concentrations [10]. Al- tal, and viral in¯uences. Modi®able environmental factors, es-
pecially acute and chronic bacterial and parasitic infections,though 8 Malawian subjects had evidence of active systemic
infection, they did not account for the elevated blood and semen may result in immune activation and increased systemic and
genital tract HIV RNA concentrations. Dissecting the relativeRNA levels in the group as a whole. Nevertheless, common
endemic infections such as tuberculosis and parasitic diseases importance of these in¯uences should enable development of
new public health initiatives to control this epidemic.could enhance viral replication while remaining clinically inap-
parent. High levels of serum immune activation markers have
been described in HIV-1±infected Africans [11]. Furthermore,
HIV-1±infected African immigrants to the United Kingdom Acknowledgments
progress at similar rates as seropositive Caucasians [12], sug-
We thank Jerry Russell and Peter Killick of John Snow Inc./gesting strong environmental in¯uences on the natural history
STAFH Project, Lilongwe, and Terrie Taylor of the Malaria Proj-of the disease.
ect, Blantyre, Malawi, for administrative and logistic support; John
Host genetic factors also in¯uence HIV-1 pathogenesis and
Schmitz and Michelle Fiordisi of the Department of Microbiology
transmission. For example, heterozygosity for the D32 CCR- and Immunology, University of North Carolina Hospitals, and
5 gene polymorphism slows progression to AIDS and is associ- Elaine Doherty-Leach and Lance Nkana from the American Em-
ated with reduced levels of plasma viral RNA [13]. The occur- bassy Clinic in Malawi for technical and laboratory support; and
rence of the polymorphic CCR-5 allele has not been described Carol Porter of the Sheps Center, Chapel Hill, for assistance with
in populations without Caucasian ancestry. HLA-linked and data management. We would like to especially thank Gina Dalla-
betta of Family Health International's AIDS Control and Preven-other genetic immune polymorphisms may also contribute to
tion Project and Lester Chitsulo of the Malawi AIDS Secretariatvarious rates of virus replication and disease progression be-
for their careful review of the manuscript.tween different populations.
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The relationship between Mycobacterium avium complex (MAC) bacteremia and proinflammatory
cytokine and human immunodeficiency virus type 1 (HIV-1) RNA levels in AIDS was investigated.
During a prospective study, blood samples were drawn monthly for mycobacterial cultures. Sera
were available at baseline and onset of MAC bacteremia from 20 cases and at corresponding times
from 19 controls. Mean interleukin-6 (IL-6) levels were 154% greater at the time of MAC bacteremia
in cases than in controls. The IL-6 levels correlated with body temperature, serum tumor necrosis
factor (TNF-a) levels, and alkaline phosphatase levels (P £ .004 for each). Although TNF-a levels
tended to rise more in MAC patients than in controls, the difference was not significant. However,
among both cases and controls, serum TNF-a levels rose significantly from baseline to the time of
last sample, irrespective of MAC infection (P  .015). Bacteremia was not associated with increased
serum HIV-1 RNA levels. Thus, early MAC bacteremia is associated with increases in serum IL-6
levels, while TNF-a levels rise over time during advanced AIDS.
Disseminated Mycobacterium avium complex (MAC) dis- HIV-infected patients, active viral replication drives progres-
sive CD4 cell depletion [4]. Current treatment strategies focusease is common during advanced AIDS. Cellular expression of
tumor necrosis factor-a (TNF-a) is induced by mycobacterial on minimizing HIV replication. The present study investigated
whether early MAC bacteremia was associated with changesproteins in vitro [1] and during tuberculosis in human immuno-
de®ciency virus (HIV)±infected persons [2]. In addition, im- in serum IL-6, TNF-a, and HIV RNA levels in patients with
AIDS.mune activating events such as febrile illnesses and immuniza-
tions cause transient increases in plasma HIV RNA. Cytokines
that promote HIV expression in vitro, such as TNF-a and
interleukin-6 (IL-6), may enhance HIV replication [3]. Among Materials and Methods
Patients. Patients previously enrolled in a prospective clinical
trial of clarithromycin prophylaxis in AIDS were studied [5]. Pa-
Received 28 February 1997; revised 18 December 1997. tients with 100 CD4/ cells/mm3 and baseline blood cultures
This study was performed with the written approval of the Vanderbilt Uni-
negative for MAC were randomized to twice daily clarithromycinversity Committee for the Protection of Human Subjects, following the guide-
or placebo. Only patients from the placebo arm were included inlines of this institution.
Grant support: Abbott Laboratories. the present analysis. Blood was drawn monthly for MAC surveil-
Reprints or correspondence: Dr. David W. Haas, Dept. of Medicine, Microbi- lance cultures, and sera were sampled every 16 weeks. All patients
ology, and Immunology, Vanderbilt University School of Medicine, 1211 21st
with adequate stored sera and for whom matched controls could beAve. S., Suite 539, Nashville, TN 37212 (david.w.haas@vanderbilt.edu).
identi®ed were included. We identi®ed 20 patients who developed
The Journal of Infectious Diseases 1998;177:1746±9
MAC bacteremia (cases). A control was selected for each (exceptq 1998 by The University of Chicago. All rights reserved.
0022±1899/98/7706±0046$02.00 1 patient who was a control for 2 cases). Cases and controls were
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